Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Côté J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, Su J, Jimenez-Zepeda VH, Song K, Louzada M, White D, Sebag M, Reiman A, Stakiw J, Kotb R, Bergstrom D, Aslam M, Kaedbey R, Venner CP, Gul E, Reece D. Côté J, et al. Among authors: gul e. Blood Cancer J. 2023 Sep 5;13(1):137. doi: 10.1038/s41408-023-00905-8. Blood Cancer J. 2023. PMID: 37669949 Free PMC article.
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Aslam M, Louzada M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: gul e. Haematologica. 2021 Jun 1;106(6):1733-1736. doi: 10.3324/haematol.2020.259093. Haematologica. 2021. PMID: 33054120 Free PMC article. No abstract available.
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Louzada M, Aslam M, Kotb R, Gul E, Atenafu E, Venner CP. Cherniawsky HM, et al. Among authors: gul e. Eur J Haematol. 2021 May;106(5):673-681. doi: 10.1111/ejh.13596. Epub 2021 Feb 16. Eur J Haematol. 2021. PMID: 33539037
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH, Venner C, McCurdy A, Masih-Khan E, Atenafu EG, Sebag M, Stakiw J, Song K, LeBlanc R, Reiman T, Louzada M, Kotb R, Gul E, Reece D. Jimenez-Zepeda VH, et al. Among authors: gul e. Br J Haematol. 2021 May;193(3):532-541. doi: 10.1111/bjh.17350. Epub 2021 Feb 9. Br J Haematol. 2021. PMID: 33559897 Clinical Trial.
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE, Hay AE. Venner CP, et al. Among authors: gul e. Am J Hematol. 2021 May 1;96(5):552-560. doi: 10.1002/ajh.26147. Am J Hematol. 2021. PMID: 33650179 Free article. Clinical Trial.
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE. Monteith BE, et al. Among authors: gul e. Eur J Haematol. 2021 Sep;107(3):333-342. doi: 10.1111/ejh.13671. Epub 2021 Jun 23. Eur J Haematol. 2021. PMID: 34053112 Clinical Trial.
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
Mian H, Eisfeld C, Venner CP, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, Khandanpour C, Lenz G, McCurdy A, Sebag M, Song K, LeBlanc R, White D, Stakiw J, Reiman A, Louzada M, Aslam M, Kotb R, Gul E, Reece D. Mian H, et al. Among authors: gul e. Front Oncol. 2022 Feb 18;12:826342. doi: 10.3389/fonc.2022.826342. eCollection 2022. Front Oncol. 2022. PMID: 35251992 Free PMC article.
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Venner CP, Masih-Khan E, Louzada M, LeBlanc R, Sebag M, Song K, Jimenez-Zepeda VH, Kotb R, Kardjadj M, Mian H, White D, Stakiw J, Aslam M, Reiman A, Gul E, Reece D. McCurdy A, et al. Among authors: gul e. Curr Oncol. 2022 Mar 2;29(3):1575-1582. doi: 10.3390/curroncol29030132. Curr Oncol. 2022. PMID: 35323332 Free PMC article.
237 results